Loading…
← CockpitCompetitor Analysis › ASMB Assembly Biosciences, Inc.Open in the cockpit ↗

Assembly Biosciences, Inc.ASMBCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 29
Mkt cap
$458M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$5.79M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$22.39
1D-0.5%
1W+0.1%
1M+5.7%
3M-33.2%
6M-14.7%
YTD-34.2%
1Y-38.4%
ATR %5.8%
Beta1.17
52w lowhigh43.6% off high

What Assembly Biosciences does

Employees: 73

Assembly Biosciences at a glance

Size Assembly Biosciences (ASMB) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $458M, the 2740th largest of 3,085 United States companies the cockpit tracks. Shares closed at $22.39 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 80.2% over the last twelve months (peer median +11.5%); the operating margin is -31.8% (peer median 6.0%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 4.9× (5th cheapest of 19).

Short interest Short interest is 14.9% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 98ASMB 84
Six months, rebased to 100: Assembly Biosciences against the median of its 20 peers (local-currency closes).

Assembly Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$67.0M$72.3M$28.5M$7.16M$0
Revenue growth—+154%+298%——
Gross profit$66.9M$72.2M$28.4M$6.71M-$498,000
EBITDA-$21.2M-$12.0M-$45.3M-$64.2M-$92.5M
Net income-$11.1M-$6.12M-$40.2M-$61.2M-$93.1M
Free cash flow-$40.7M-$41.2M-$51.1M$22.5M-$84.6M
Capital expenditure$164,000$66,000$28,000$255,000$102,000
Total debt$2.21M$2.63M$3.09M$2.34M$3.46M

Quarterly statements and history in the cockpit →

Assembly Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%002693GUFICBIOKPLCAPR002370EOLS6620000640301201603811RPGLIFEAQST002462SMSPHARMA600624HNSARGNXASMB6-month return →1-month return →
Up and to the right = strong over both horizons. Assembly Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×5×10×15×002693GUFICBIOKPL002370EOLS60356666200006403012016038113705RPGLIFEAQST002462600624HNSAASMBRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Assembly Biosciences is the large dot.

Assembly Biosciences competitors and peer comparison

How Assembly Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Assembly Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureASMBPeer medianRank in peer set
1-month return+5.7%-4.2%6th highest of 21
6-month return-14.7%-0.4%8th lowest of 20
Distance from 52-week high-43.6%-32.1%8th lowest of 21
Revenue growth (TTM)+80.2%+11.5%highest of 20
Operating margin-31.8%6.0%5th lowest of 19
EV / Sales2.2×4.9×5th cheapest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%3.4×1.3%+1.3%
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%5.3×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%0.2×-9.9%-3.4%
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a

Questions

Which companies are Assembly Biosciences's closest peers?
The cockpit's peer set: BlossomHill Therapeutics (BLSM), Hainan Shuangcheng Pharmaceuticals (002693.SZ), Gufic Biosciences (GUFICBIO.NS), Kwality Pharmaceuticals (KPL.NS), Capricor Therapeutics (CAPR), Zhejiang Yatai Pharmaceutical (002370.SZ), Evolus (EOLS), Pulike Biological Engineering (603566.SS).
Is Assembly Biosciences expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 4.9×, 5th cheapest of 19 in its peer set.
How has Assembly Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -0.4% for the median peer; over one year -38.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.